< Return to News

West at ASCO Annual Meeting

Wednesday, June 13, 2018
CATEGORIES: ,
West Cancer Center had an impressive presence at the American Society of Clinical Oncology Annual Meeting.


Lee Schwartzberg:
​Predicting expected absolute chemotherapy treatment benefit in women with early-stage breast cancer using a 12-gene expression assay.

In silico evaluation of the 12-gene molecular score (EndoPredict) and the recurrence score (Oncotype DX) as predictors of response to neo-adjuvant chemotherapy in estrogen receptor positive (ER+), HER2 negative (HER2-) breast cancer.


Precision Oncology: Who, How, What, When, and When Not?TOPACIO/Keynote-162: Niraparib + pembrolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC), a phase 2 trial.Activity of tesetaxel, an oral taxane, given as a single-agent in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC) in a phase 2 study.

Contessa: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC).​

Ari VanderWalde:

Co-expression patterns of immune checkpoint molecules in relation to PD-L1 expression.


Combining ipilimumab (ipi) and nivolumab (nivo) in advanced melanoma following progression on a PD-1 inhibitor (SWOG S1616).


Incidence of Neuregulin1 (NRG1) gene fusions across tumor types.Noam VanderWalde:

Phase 2 randomized study of a walking intervention for radiation-related fatigue among older breast cancer patients receiving radiation.


Survival outcomes for various treatment modalities in early-stage grade 3 follicular lymphoma (FL3): a National Cancer Database (NCDB) study.



Jason Chandler:

A multicenter study of the Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib plus durvalumab in patients with relapsed/refractory (R/R) solid tumors.


Avelumab (anti–PD-L1) in patients with platinum-treated advanced NSCLC: 2.5-year follow-up from the JAVELIN Solid Tumor trial.


Ublituximab and ibrutinib for previously treated genetically high-risk chronic lymphocytic leukemia: Results of the GENUINE phase 3 study.


Analysis of 1261 metastatic cancer patients evaluated by comprehensive molecular profiling (CMP) including next-gen sequencing (NGS) from a single institution.


Safety profile of nivolumab administered as 30-minute (min) infusion: Analysis of data from CheckMate 153.
Social connectivity and outcomes for adolescents and young adults (AYAs) with acute lymphoblastic leukemia (ALL).


Avelumab (MSB0010718C; anti-PD-L1) in patients with advanced cancer: safety data from 1300 patients enrolled in the phase 1b JAVELIN Solid Tumor trial.​